Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.42 |
| ▸ | CDK9 | P50750 | 4/20 | 0.42 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 6/20 | 0.40 |
| ▸ | BCR | P11274 | 5/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.37 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.37 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1242168 | 0.94 | PIP4K2C (0.45) | PTGS1CCNT1CDK9PIP4K2CELANE | |
| SCHEMBL1244474 | 0.94 | CDK9 (0.46) | PTGS1CCNT1CDK9PIP4K2CABL1 | |
| Trifluoroacetic Acid SCHEMBL1243561 | 0.90 | LOXL2 (0.41) | PIP4K2CABL1BCRKDM4EMAPT | |
| Trifluoroacetic Acid SCHEMBL1243690 | 0.89 | CYP1A2 (0.41) | CCNT1CDK9ABL1BCRKDM4E | |
| Trifluoroacetic Acid SCHEMBL4384220 | 0.89 | PIP4K2C (0.39) | PIP4K2CABL1BCRKDM4EMAPT | |
| SCHEMBL1243847 | 0.88 | PIP4K2C (0.49) | CCNT1CDK9PIP4K2CELANEKDM4E | |
| Trifluoroacetic Acid SCHEMBL1244577 | 0.88 | ALDH1A1 (0.40) | CCNT1CDK9PIP4K2CABL1BCR | |
| SCHEMBL1243893 | 0.88 | PIP4K2C (0.51) | CCNT1CDK9PIP4K2CKDM4EMAPT | |
| Trifluoroacetic Acid SCHEMBL1244312 | 0.88 | PIP4K2C (0.45) | PIP4K2CABL1BCRKDM4EMAPT | |
| Trifluoroacetic Acid SCHEMBL1242107 | 0.88 | PTGS1 (0.40) | PTGS1CCNT1CDK9PIP4K2CABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1763526-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Altana Pharma AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000589-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | PTGS1 2191/4885CCNT1 343/4885CDK9 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.